Recurrence: all 3,523 studies

Page 9 of 36. Open to participants first (870), then studies with results posted, then the rest; newest registration first within each.

• Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLCRecruitingNCT04467723Phase 1/2
• A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory LymphomasRecruitingNCT04458389Phase 1/2
• Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
• The Impact of Frequenting a Social Leg Program on Therapeutic Adherence and Venous Leg Ulcer Wound Healing OutcomesNot yet recruitingNCT04370106Not applicable
• Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
• A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid MalignanciesRecruitingNCT04283006Early Phase 1
• Three Times Weekly Symptom Screening for Children With CancerNot yet recruitingNCT04275102Not applicable
• Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent GliomasRecruitingNCT04267978Phase 2
• RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph NodesRecruitingNCT04266327Not applicable
• Endoscopic Resection of Large Colorectal Polyps: An Observational Cohort StudyRecruitingNCT04220905
• Cabozantinib to Treat Recurrent Liver Cancer Post TransplantRecruitingNCT04204850Phase 2
• Prospective Collection of Samples for Urothelial Cancer of BladderNot yet recruitingNCT04167332
• SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsRecruitingNCT04150042Phase 1
• A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04129710Phase 2
• Study of Out of Specification for TisagenlecleucelRecruitingNCT04094311Phase 3
• Hepatocarcinoma Recurrence on the Liver Study - Part2Not yet recruitingNCT04053231
• CLAG-GO for Patients With Persistent, Relapsed or Refractory AMLRecruitingNCT04050280Phase 2
• Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids TaperingRecruitingNCT04012905Phase 3
• A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological MalignanciesAvailableNCT04008524
• DAHANCA 37. Re-irradiation With Proton RadiotherapyRecruitingNCT03981068Not applicable
• Prospective Sample Collection for Cancer of BladderRecruitingNCT03973671
• A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingNCT03970447Phase 2/3
• The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal CancerNot yet recruitingNCT03923335
• Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT03850574Phase 1/2
• Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic MalignanciesRecruitingNCT03838926Phase 1
• Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaRecruitingNCT03826992Phase 1
• Cell Free DNA for the Diagnosis and Treatment in Early NSCLCRecruitingNCT03791034
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT03761108Phase 1/2
• Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer PatientsRecruitingNCT03731442Phase 3
• Robot-assisted Approach to Cervical CancerRecruitingNCT03719547Not applicable
• Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714RecruitingNCT03691077Phase 3
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsRecruitingNCT03686124Phase 1/2
• IA Carboplatin + Radiotherapy in Relapsing GBMRecruitingNCT03672721Phase 1/2
• Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder CancerRecruitingNCT03664869Phase 3
• Immunotherapy for the Treatment of Advanced Solid TumorRecruitingNCT03658785Phase 1/2
• Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)RecruitingNCT03643549Phase 1/2
• Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03618550Phase 2
• A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological MalignanciesRecruitingNCT03557619Phase 1
• New MRI Biomarkers in Head and Neck CancersRecruitingNCT03483337
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaRecruitingNCT03460977Phase 1
• Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALLRecruitingNCT03407859Early Phase 1
• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingNCT03328078Phase 1/2
• SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03250962Phase 2
• Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T CellsRecruitingNCT03236129Phase 3
• RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal DissectionRecruitingNCT03183115Not applicable
• Expanded Access to VenetoclaxAvailableNCT03123029
• Stroke Registration of Young Adults in ChinaRecruitingNCT03024164
• A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic PheochromocytomaAvailableNCT03015844
• Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingNCT02974647Phase 2
• Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory MalignanciesRecruitingNCT02961101Phase 1/2
• Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast CancerRecruitingNCT02926690Phase 1
• A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung CancerRecruitingNCT02889666Phase 1
• Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell LymphomasRecruitingNCT02859402Phase 2
• Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible Mesh With or Without LiquiBand Fix 8 Mesh FixationRecruitingNCT02781870Not applicable
• Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute LeukemiaRecruitingNCT02677064
• Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular LymphomaRecruitingNCT02438501Phase 3
• MRI/Ultrasound Fusion Guided Prostate CryotherapyRecruitingNCT02381990
• Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingNCT02343042Phase 1/2
• Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in ChildrenRecruitingNCT02235857Not applicable
• Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic MalignanciesRecruitingNCT02203903Phase 1
• The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort StudyRecruitingNCT02138695
• Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationRecruitingNCT02074839Phase 1
• Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid TumorsRecruitingNCT02013336Phase 1
• Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)RecruitingNCT01853631Phase 1
• Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer TreatmentRecruitingNCT01790152
• 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use ProtocolAvailableNCT01370330
• Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingNCT01356290Phase 2
• ENDOMET - Novel Diagnostic Tools and Treatments for EndometriosisRecruitingNCT01301885
• Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory MyelomaRecruitingNCT00800059Phase 1/2
• Pituitary Tumor Surveillance: Pathogenic CorrelationRecruitingNCT00599092
• Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedNCT06984328Phase 2Results posted
• Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical CarcinomasTerminatedNCT06865677Phase 2Results posted
• A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT06055075Phase 1/2Results posted
• Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)CompletedNCT06004167Not applicableResults posted
• Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT05986682Results posted
• Isa-Pom-Dex in Elderly/Frail Subjects With RRMMActive, not recruitingNCT05911321Phase 2Results posted
• Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLTerminatedNCT05883449Phase 2Results posted
• A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsTerminatedNCT05787496Phase 1Results posted
• Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line ChemotherapyCompletedNCT05718466Phase 3Results posted
• Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyTerminatedNCT05714345Phase 2Results posted
• C-Cog in Early Course Schizophrenia StudyTerminatedNCT05662306Phase 4Results posted
• Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedNCT05626322Phase 1/2Results posted
• A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last TreatmentCompletedNCT05597085Results posted
• A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell MalignanciesTerminatedNCT05588440Phase 1/2Results posted
• Study of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesTerminatedNCT05537766Phase 2Results posted
• Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT05498220Phase 2Results posted
• A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerTerminatedNCT05275673Phase 2Results posted
• Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial CancerTerminatedNCT05263492Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationCompletedNCT05253807Phase 2Results posted
• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT05216835Phase 1Results posted
• AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHLCompletedNCT05140382Phase 2Results posted
• Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple SclerosisCompletedNCT05116540Phase 2Results posted
• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT05064358Phase 2Results posted
• A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)TerminatedNCT05038800Phase 1Results posted
• A Study of E7820 in People With Bone Marrow (Myeloid) CancersCompletedNCT05024994Phase 2Results posted
• A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingNCT05020015Phase 2Results posted
• A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to TreatmentCompletedNCT05014412Phase 2Results posted
• Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT05008055Phase 2Results posted
• A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Phase 3Results posted
• Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompletedNCT04930536Phase 4Results posted

← Recurrence overview